Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?
Jim Hoffman, Independent Consultant, shared a post on LinkedIn about recent articles, adding:
“ST-elevation myocardial infarction (STEMI) plus COVID-19 patients had nearly 4 times higher death rates than pre-pandemic controls (45% vs 11%), Even STEMI hospital survivors faced lasting risk; the mortality gradient didn’t stop at discharge.
Persistent One-Year Mortality Gradient After STEMI and COVID-19: Long-Term Outcomes From the NACMI
STEMI patients, like LC PASC patients, have exacerbated ‘NETosis dysregulation.’
Many STEMI patients have been shown to have lower but still elevated NETs even after Percutaneous Cornary Intervention.
Keeping their NETs lower could likely help prevent recurrence and also improve microvascular blood circulation and tissue perfusion.
NETosis in Cardiovascular Disease: An Opportunity for Personalized Antithrombotic Treatments?
Neutrophil extracellular traps (NETs) in patients with STEMI.
Association with percutaneous coronary intervention and antithrombotic treatments.
A NET removal therapy that should be trialed before, during, and post-treatment for STEMI/thrombectomy and for LC PASC where persistent NETs are also elevated, contributing to hypermicroclotting and risk for larger thrombotic complications.”
Title 1: Persistent One-Year Mortality Gradient After STEMI and COVID-19: Long-Term Outcomes From the NACMI Registry
Authors: Payam Dehghani, Chase J. Ellingson, BKina, Jyotpal Singh, Ellen Cravero, G.B. John Mancini, Larissa Stanberry, Mina Madan, Catherine P. Benziger, Nima Ghasemzadeh, Anna E. Bortnick, Rohan Kankaria, Cindy L. Grines, Keshav Nayak, Ehtisham Mahmud, Kevin R. Bainey, M. Chadi Alraies, Akshay Bagai, Rajan A.G. Patel, Shy Amlani, Brian C. Case, Ron Waksman, Jay S. Shavadia, Jay H. Stone, Deepak Acharya, Nosheen Javed, Rodrigo Bagur, Ross Garberich, Santiago Garcia, Timothy D. Henry
Title 2: NETosis in Cardiovascular Disease: An Opportunity for Personalized Antithrombotic Treatments?
Authors: Constance C.F.M.J. Baaten, Magdolna Nagy, Constance C.F.M.J. Baaten , Magdolna Nagy , Henri M.H. Spronk, Hugo Ten Cate , Bas L.J.H. Kietselaer
Title 3: Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments
Authors: Maria Ferré-Vallverdúa, Ana María Latorrec, María Paz Fusetb, Elena Sáncheza, Isabel Madridb, Francisco Tena, Juana Vallésc, María Teresa Santosc, Santiago Bonanadc, Antonio Moscardó
Title 4: Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients
Authors: Alain R Thierry, Tom Usher, Cynthia Sanchez, Simone Turner, Chantelle Venter, Brice Pastor, Maxine Waters, Anel Thompson, Alexia Mirandola, Ekaterina Pisareva, Corinne Prevostel, Gert J Laubscher, Douglas B Kell, Etheresia Pretorius
Other posts featuring Jim Hoffman on Hemostasis Today.
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator
-
Aug 24, 2026, 14:58Danny Hsu: Rethinking Bleeding Risk in Patients on Anticoagulation
-
Aug 24, 2026, 14:18The Way to a Safer Workplace for People With Bleeding Disorders – EHC